Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Dow
Colorcon
McKesson
Johnson and Johnson

Last Updated: September 25, 2022

LUPRON DEPOT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Lupron Depot patents expire, and when can generic versions of Lupron Depot launch?

Lupron Depot is a drug marketed by Abbvie Endocrine Inc and is included in five NDAs. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-one countries.

The generic ingredient in LUPRON DEPOT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lupron Depot

A generic version of LUPRON DEPOT was approved as leuprolide acetate by SANDOZ on August 4th, 1998.

  Try it Free

Summary for LUPRON DEPOT
Drug patent expirations by year for LUPRON DEPOT
Drug Prices for LUPRON DEPOT

See drug prices for LUPRON DEPOT

Recent Clinical Trials for LUPRON DEPOT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 4
National Cancer Institute (NCI)Phase 4
ParexelPhase 2

See all LUPRON DEPOT clinical trials

US Patents and Regulatory Information for LUPRON DEPOT

LUPRON DEPOT is protected by two US patents.

Patents protecting LUPRON DEPOT

Controlled release composition and method of producing the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sustained-release composition and method for producing the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PALLIATIVE TREATMENT OF PROSTATE CANCER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020011-001 Oct 22, 1990 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-003 Jun 17, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020708-001 Mar 7, 1997 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-005 Jan 21, 1994 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-003 Jun 17, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-006 Jan 21, 1994 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020011-002 Oct 26, 1995 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LUPRON DEPOT

International Patents for LUPRON DEPOT

See the table below for patents covering LUPRON DEPOT around the world.

Country Patent Number Title Estimated Expiration
Spain 8703739 See Plans and Pricing
Japan 2010513225 See Plans and Pricing
Japan H04321622 LONG PERIOD SUSTAINED RELEASE TYPE MICRO CAPSULE See Plans and Pricing
South Korea 100961413 See Plans and Pricing
Japan 3277342 See Plans and Pricing
Austria 39935 See Plans and Pricing
Poland 204903 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Mallinckrodt
Moodys
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.